NPPA gets Delhi HC notice on AstraZeneca plea over cancer drug Tagrisso
Advertisement
New Delhi: The Delhi High Court on Monday issued notice to National Pharmaceutical Pricing Authority (NPPA) and others on AstraZeneca Pharma India's petition challenging notice relating to Tagrisso 80 mg tablets.
A Division Bench of Justices DN Patel and Jyoti Singh asked NPPA and others to file their replies to the petition filed by AstraZeneca Pharma and listed the matter for August 20, reports ANI.
AstraZeneca Pharma has sought quashing of the demand notice issued by NPPA for an amount of Rs 157 crores.
The NPPA had issued a notice alleging that the company has overcharged about Rs 157.38 crores during the period from March 8, 2019, to January 31, 2021, in respect of Tagrisso (Osimertinib) 80 mg tablets.
Medical Dialogues team had earlier reported that AstraZeneca had claimed that it has a product patent covering the molecule OSIMERTINIB (TAGRISSO) and the same is valid for twenty years, i.e. up to 24.07.2032, making the Show Cause Notice dated 14.10.2020 and the impugned order dated 13.01.2021 issued by NPPA thus illegal and to be quashed.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.